Your browser doesn't support javascript.
loading
Stretch-activated ion channel TMEM63B associates with developmental and epileptic encephalopathies and progressive neurodegeneration.
Vetro, Annalisa; Pelorosso, Cristiana; Balestrini, Simona; Masi, Alessio; Hambleton, Sophie; Argilli, Emanuela; Conti, Valerio; Giubbolini, Simone; Barrick, Rebekah; Bergant, Gaber; Writzl, Karin; Bijlsma, Emilia K; Brunet, Theresa; Cacheiro, Pilar; Mei, Davide; Devlin, Anita; Hoffer, Mariëtte J V; Machol, Keren; Mannaioni, Guido; Sakamoto, Masamune; Menezes, Manoj P; Courtin, Thomas; Sherr, Elliott; Parra, Riccardo; Richardson, Ruth; Roscioli, Tony; Scala, Marcello; von Stülpnagel, Celina; Smedley, Damian; Torella, Annalaura; Tohyama, Jun; Koichihara, Reiko; Hamada, Keisuke; Ogata, Kazuhiro; Suzuki, Takashi; Sugie, Atsushi; van der Smagt, Jasper J; van Gassen, Koen; Valence, Stephanie; Vittery, Emma; Malone, Stephen; Kato, Mitsuhiro; Matsumoto, Naomichi; Ratto, Gian Michele; Guerrini, Renzo.
Afiliação
  • Vetro A; Neuroscience Department, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Pelorosso C; Neuroscience Department, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Balestrini S; Neuroscience Department, Meyer Children's Hospital IRCCS, Florence, Italy; University of Florence, Florence, Italy.
  • Masi A; Department of Neuroscience, Psychology, Drug Research and Child Health (NeuroFarBa), Section of Pharmacology and Toxicology, University of Florence, Florence, Italy.
  • Hambleton S; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK; Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Argilli E; Department of Neurology and Institute of Human Genetics and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
  • Conti V; Neuroscience Department, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Giubbolini S; National Enterprise for NanoScience and NanoTechnology (NEST), Istituto Nanoscienze, Consiglio Nazionale delle Ricerche (CNR) and Scuola Normale Superiore Pisa, Pisa, Italy.
  • Barrick R; Division of Metabolic Disorders, Children's Hospital of Orange County (CHOC), Orange, CA, USA.
  • Bergant G; Clinical Institute of Genomic Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
  • Writzl K; Clinical Institute of Genomic Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
  • Bijlsma EK; Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands.
  • Brunet T; Institute of Human Genetics, School of Medicine, Technical University Munich, Munich, Germany; Department of Pediatric Neurology and Developmental Medicine, Dr. v. Hauner Children's Hospital, LMU - University of Munich, München, Germany.
  • Cacheiro P; William Harvey Research Institute, Queen Mary University of London, London, UK.
  • Mei D; Neuroscience Department, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Devlin A; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK; Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Hoffer MJV; Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands.
  • Machol K; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
  • Mannaioni G; Department of Neuroscience, Psychology, Drug Research and Child Health (NeuroFarBa), Section of Pharmacology and Toxicology, University of Florence, Florence, Italy.
  • Sakamoto M; Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama 236-0004 Japan.
  • Menezes MP; Department of Neurology, The Children's Hospital at Westmead and the Children's Hospital at Westmead Clinical School, University of Sydney, Westmead NSW, Australia.
  • Courtin T; Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Paris, France; Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Génétique, DMU BioGeM, Paris, France.
  • Sherr E; Department of Neurology and Institute of Human Genetics and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
  • Parra R; National Enterprise for NanoScience and NanoTechnology (NEST), Istituto Nanoscienze, Consiglio Nazionale delle Ricerche (CNR) and Scuola Normale Superiore Pisa, Pisa, Italy.
  • Richardson R; Northern Genetics Service, Newcastle upon Tyne hospitals NHS Foundation Trust, Newcastle, UK.
  • Roscioli T; New South Wales Health Pathology Randwick Genomics, Prince of Wales Hospital, Sydney, NSW 2031, Australia; Neuroscience Research Australia, Sydney, NSW 2031, Australia.
  • Scala M; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.
  • von Stülpnagel C; Department of Pediatric Neurology and Developmental Medicine, Dr. v. Hauner Children's Hospital, LMU - University of Munich, München, Germany; Institute for Transition, Rehabilitation and Palliation, Paracelsus Medical University, Salzburg, Austria.
  • Smedley D; William Harvey Research Institute, Queen Mary University of London, London, UK.
  • Torella A; Department of Precision Medicine, University "Luigi Vanvitelli," Naples, Italy; Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy.
  • Tohyama J; Department of Child Neurology, Nishi-Niigata Chuo National Hospital, Niigata 950-2085, Japan.
  • Koichihara R; Department for Child Health and Human Development, Saitama Children's Medical Center, Saitama 330-8777, Japan.
  • Hamada K; Department of Biochemistry, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
  • Ogata K; Department of Biochemistry, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
  • Suzuki T; School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Kanagawa, Japan.
  • Sugie A; Brain Research Institute, Niigata University, Niigata 951-8585, Japan.
  • van der Smagt JJ; Department of Genetics, University Medical Center Utrecht, Utrecht, the Netherlands.
  • van Gassen K; Department of Genetics, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Valence S; Centre de référence Maladies Rares "Déficience intellectuelle de cause rare," Sorbonne Université, Paris, France; Département de Neuropédiatrie, Hôpital Armand Trousseau, APHP, Sorbonne Université, Paris, France.
  • Vittery E; Northern Genetics Service, Newcastle upon Tyne hospitals NHS Foundation Trust, Newcastle, UK.
  • Malone S; Department of Neurosciences, Queensland Children's Hospital, Brisbane QLD, Australia; Centre for Advanced Imaging, University of Queensland, St Lucia QLD, Australia.
  • Kato M; Department of Pediatrics, Showa University School of Medicine, Tokyo 142-8666, Japan.
  • Matsumoto N; Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama 236-0004 Japan.
  • Ratto GM; National Enterprise for NanoScience and NanoTechnology (NEST), Istituto Nanoscienze, Consiglio Nazionale delle Ricerche (CNR) and Scuola Normale Superiore Pisa, Pisa, Italy; Istituto Neuroscienze CNR, Padova, Italy.
  • Guerrini R; Neuroscience Department, Meyer Children's Hospital IRCCS, Florence, Italy; University of Florence, Florence, Italy. Electronic address: r.guerrini@meyer.it.
Am J Hum Genet ; 110(8): 1356-1376, 2023 08 03.
Article em En | MEDLINE | ID: mdl-37421948
ABSTRACT
By converting physical forces into electrical signals or triggering intracellular cascades, stretch-activated ion channels allow the cell to respond to osmotic and mechanical stress. Knowledge of the pathophysiological mechanisms underlying associations of stretch-activated ion channels with human disease is limited. Here, we describe 17 unrelated individuals with severe early-onset developmental and epileptic encephalopathy (DEE), intellectual disability, and severe motor and cortical visual impairment associated with progressive neurodegenerative brain changes carrying ten distinct heterozygous variants of TMEM63B, encoding for a highly conserved stretch-activated ion channel. The variants occurred de novo in 16/17 individuals for whom parental DNA was available and either missense, including the recurrent p.Val44Met in 7/17 individuals, or in-frame, all affecting conserved residues located in transmembrane regions of the protein. In 12 individuals, hematological abnormalities co-occurred, such as macrocytosis and hemolysis, requiring blood transfusions in some. We modeled six variants (p.Val44Met, p.Arg433His, p.Thr481Asn, p.Gly580Ser, p.Arg660Thr, and p.Phe697Leu), each affecting a distinct transmembrane domain of the channel, in transfected Neuro2a cells and demonstrated inward leak cation currents across the mutated channel even in isotonic conditions, while the response to hypo-osmotic challenge was impaired, as were the Ca2+ transients generated under hypo-osmotic stimulation. Ectopic expression of the p.Val44Met and p.Gly580Cys variants in Drosophila resulted in early death. TMEM63B-associated DEE represents a recognizable clinicopathological entity in which altered cation conductivity results in a severe neurological phenotype with progressive brain damage and early-onset epilepsy associated with hematological abnormalities in most individuals.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Encefalopatias / Deficiência Intelectual Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Am J Hum Genet Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Encefalopatias / Deficiência Intelectual Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Am J Hum Genet Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália
...